Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to investigate the drug-drug interactions between ACT-541468 and ethanol in healthy subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment A (ethanol + ACT-541468) | Experimental | 5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg) |
|
| Treatment B (ethanol placebo + ACT-541468) | Experimental | 5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg) |
|
| Treatment C (ethanol + ACT-541468 placebo) | Experimental | 5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo |
|
| Treatment D (ethanol placebo + ACT-541468 placebo) | Experimental | 5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ACT-541468 | Drug | One tablet of 50 mg ACT-541468 will be administered orally. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline for saccadic peak velocity (degrees/sec) to assess sedation | Several timepoints on Day 1; for up to 24 hours post-dose |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline for smooth pursuit (%) to assess eye movement coordination and attention | Several timepoints on Day 1; for up to 24 hours post-dose | |
| Change from baseline for adaptive tracking (%) to assess visuo-motor control and vigilance | Several timepoints on Day 1; for up to 24 hours post-dose |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pascale Gasser | Idorsia Pharmaceuticals Ltd. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre For Human Drug Research | Leiden | 2333 | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33205362 | Derived | Berger B, Brooks S, Zuiker R, Richard M, Muehlan C, Dingemanse J. Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS Drugs. 2020 Dec;34(12):1253-1266. doi: 10.1007/s40263-020-00768-8. Epub 2020 Nov 18. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000634383 | daridorexant |
| C001166 | ethanol lumiflavine |
Not provided
Not provided
Not provided
Double-dummy, four-way crossover study design
Not provided
Not provided
Not provided
| ACT-541468 placebo | Other | Matching ACT-541468 placebo will be administered orally as 1 tablet. |
|
| Ethanol 10% | Other | Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L. |
|
| Ethanol placebo | Other | Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h. |
|
| Change from baseline for body sway (antero-posterior in mm / 2 min) to assess postural stability | Several timepoints on Day 1; for up to 24 hours post-dose |
| Change from baseline for visual analog scales (VAS) Bond & Lader to assess subjective alertness, mood, and calmness | Several timepoints on Day 1; for up to 24 hours post-dose |
| Change from baseline for VAS for alcohol intoxication to assess subjective effects of ethanol | Several timepoints on Day 1; for up to 24 hours post-dose |
| ACT-541468 PK endpoints for treatments A and B: Area under the plasma concentration-time curve (AUC) from time zero to 24 h (AUC0-24) | Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose |
| ACT-541468 PK endpoints for treatments A and B: AUC from zero to infinity (AUC0-∞) | Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose |
| ACT-541468 PK endpoints for treatments A and B: Maximum plasma concentration (Cmax) | Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose |
| ACT-541468 PK endpoints for treatments A and B: Time to reach Cmax (tmax) | Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose |
| ACT-541468 PK endpoints for treatments A and B: Terminal elimination half-life (t½) | Several timepoints from Day 1 to Day 2 (EOT/EOS); for up to 24 hours post-dose |
| Ethanol PK endpoints for treatments A and C: Breath ethanol concentrations (BrEC) | Several timepoints on Day 1; for up to 24 hours post-dose |
| Ethanol PK endpoints for treatments A and C: Total ethanol dose (in grams) required to maintain the 0.6 g/L ethanol clamp | Several timepoints on Day 1; for up to 5 hours |
| Safety endpoints: Treatment-emergent AEs from study treatment administration up to EOT in each treatment period | AEs from Day 1 to Day 2 (EOT/EOS); for up to 2 days post-dose |
| Safety endpoints: Treatment-emergent SAEs from study treatment administration up to EOT in each treatment period | SAEs from Screening to Safety follow up; for up to 14 weeks |